Aminoglycoside antibiotics

Aminoglycosides

- Streptomycin 1944
- Actinomycetes Streptomyces griseus
- Bactericidal antibiotics
- Interfere with protein synthesis
- Used to treat aerobic Gram –ve bacteria
- Resemble each other in MOA, pharmacokinetic therapeutic and toxic properties
- Relatively low margin of safety
- Exhibit ototoxicity and nephrotoxicity

Chemistry

Amino sugar -o- 2-deoxystreptamine -o- Amino sugar

Aminoglycosides Structure

Streptidine -o- Streptose amino sugar Streptomycin structure

Streptobiosamine Streptobiosamine


Aminoglycosides

- Systemic
 - Streptomycin
 - Gentamicin
 - Kanamycin
 - Amikacin
 - Sisomicin
 - Tobramycin
 - Netilimicin


- Topical
 - Neomycin
 - Framycetin

Mechanism of Protein synthesis


Formation of the Initiation Complex




Joining of 50S Ribosomal Subunit



Protein Elongation




Termination of Translation



Mechanism of action


- Initially they penetrate bacterial cell wall, to reach periplasmic space through porin channels (passive diffusion)
- Further transport across
 cytoplasmic membrane takes
 place by active transport by
 proton pump; an oxygen dependent process

Gram Negative



Mechanism of Action

- Bind 30S ribosomal subunits and interfere the initiation complex
- Induce misreading of genetic code on mRNA
- Breakup of polysomes into monosomes



Post antibiotic effect

- Aminoglycosides exhibit concentration dependent killing.
- They also possess significant Post-antibiotic effect.
- Single daily dosing at least as effective as and no more toxic than multiple dosing.

Mechanism of resistance

- Synthesis of plasmid mediated bacterial transferase enzyme: Inactivate aminoglycosides
- transport into bacterial cytosol
- Deletion/alteration of receptor protein on 30 S ribosomal unit by mutation: prevents attachment


Antibacterial spectrum

- Primarily against Gm –ve aerobic bacilli
 - Proteus, pseudomonas
 - E.Coli, enterobacter
 - Klebsiella
 - Shigella
- Only few Gm +ve cocci:
 - staph aureus, strepto viridans
- Not effective against Gm +ve bacilli, Gm-ve cocci and anaerobes

Pharmacokinetics

- Highly polar basic drugs: poor oral BA
- Administered parenterally or applied locally
- Poorly distributed and poorly protein bound
- Do not undergo any significant metabolism
- Nearly all IV dose is excreted unchanged in urine
- Dose adjustment is needed in renal insufficiency

Pharmacokinetics



Dose for a case of renal insufficiency

Normal therapeutic doseSr creatinine value (mg/dl)

Dose for a case of renal insufficiency

Cockroft gault formula:

$$CrCl = (140-age) \times weight [kg]$$

(sCr x 72)


- For females multiply above value by 0.85
- Corrected dose = <u>Normal dose x pt CrCl</u>
 Normal CrCl

Clinical uses

- Gram –ve bacillary infection
 - Septicaemia, pelvic & abdominal sepsis
- Bacterial endocarditis
 - enterococcal, streptococcal or staphylococcal infection of heart valves
- Pneumonias, Tuberculosis
- Tularemia
- Plague, Brucellosis
- Topical Neomycin, Framycetin.
- Infections of conjunctiva or external ear
- To sterilize the bowel of patients who receive immunosuppressive therapy, before surgery & in hepatic coma

Shared toxicities

- Ototoxicity
 - Vestibular damage
 - Cochlear damage
- Nephrotoxicity
- Neuromuscular blockade



Ototoxicity

- Impairment of VIII cranial nerve function
- May be irreversible
- Cochlear damage
 - Hearing loss and tinnitus
 - More with neomycin, amikacin and kanamycin
- Vestibular damage
 - Vertigo, ataxia, loss of balance
 - More with Streptomycin, gentamycin
- Tobramycin has both types of toxicity
- Netilimycin claimed to have low ototoxicity

Nephrotoxicity

- Gentamicin, amikacin and tobramycin are more toxic than streptomycin
- Responsible for 10-15% of all renal failure cases
- Reversible if drug promptly discontinued
- ↓ GFR, ↑ sr creatinine
- ↓clearance of antibiotic → ↑ ototoxicity

Neuromuscular blockade

- Cause N-M junction blockade by
 - Displacing Ca²⁺ from NM junction
 - By blocking post synaptic N_M receptors
 - Inhibiting Ach release from motor nerve
- Neomycin & streptomycin: more propensity
- Tobramycin least likely to produce it
- Myasthenic weakness †by these drugs

Precautions / Contraindications

- Pregnancy: foetal ototoxicity
- With other ototoxic drugs: furosemide, minocycline
- With nephrotoxic drugs: vancomycin ,cisplatin
- Elderly patients
- Those with kidney disease
- Cautious use of muscle relaxants
- Do not mix with any other drug in same syringe

Streptomycin

- Ribosomal resistance develops fast
- Limited usefulness as single agent
- Plague, tularemia and brucellosis
 - In combination with tetracycline
- SABE: due to Streptococcus Viridans & faecalis
 - With penicillin but gentamicin preferred
- Reserve first line drug for tuberculosis used only in combination

Gentamicin

- Obtained from Micromonospora purpurea
- Most commonly used aminoglycoside
 - More potent than Streptomycin
 - Broader spectrum: pseudomonas, proteus, E.coli, klebsiella, enterobacter, serratia
 - Low cost, reliability of use, long experience
 - Acts synergistically with ampicillin, penicillin G,
 Ticarcillin, ceftriaxone, Vancomycin
- Ineffective against M.tuberculosis
- Relatively more nephrotoxic

Gentamicin (Uses)

- Use restricted to serious Gm-ve bacillary infections
- Septicaemia, sepsis, fever in immunocompromised patients
 - Used with penicillins
- Pelvic infections: with metronidazole
- SABE: with Penicillin G or ampicillin or vancomycin
- Coliform infection: with ampicillin or ceftriaxone
- Pseudomonal infections: with ticarcillin
- Meningitis by Gm-ve bacilli : III generation cephalosporin alone or with gentamicin

Guideline for adjustment of dose in renal insufficiency

Creatinine clear. (ml/min)	% Maximal daily dosing	Frequency of dosing
100	100	Every 24 hr
75	75	(3.7)
50	50	, ,
25	25	,,
20	80	Every 48 hr
10	60	,,
< 10	40	,,

Tobramycin

- Identical to gentamicin
- Used in pseudomonas and proteus infections
- Ototoxicty and nephrotoxicity probably lower

Sisomicin

- Identical to gentamicin
- More potent on pseudomonas and β -hemolytic streptococci
- Used interchangeably with gentamicin

Amikacin

- Less toxic semisynthetic derivative of kanamycin
- Resistant to enzymes that inactivate gentamicin and tobramcyin
- Widest spectrum of activity
- Uses:
 - Same as gentamicin
 - Reserve drug for hospital acquired Gm-ve bacillary infections
 - Multidrug resistant TB along with other drugs
- Dose: 15mg/kg/day in 1-3 doses

Netilimicin

- Semisynthetic derivative of sisomicin
- Relatively resistant to aminoglycoside inactivating enzymes
- More active against klebsiella, enterobacter & staphylococci
- Less active against pseudomonas aeruginosa
- Doses and pharmacokinetics similar to gentamicin

Neomycin

- wide spectrum active against Gm-ve bacilli and some gm+ve cocci
- Pseudomonas and strep.pyogenes not sensitive
- Too toxic for parenteral use, limited to topical use

Neomycin (uses)

- Topically used in skin, eye and external ear infections combined with bacitracin or polymyxin-B to widen antibacterial spectrum and to prevent emergence of resistant strains
- Orally
 - Preparation of bowel before surgery 1 gm TDS
 - Hepatic coma: Supresses ammonia forming coliforms prevents encephalopathy (Lactulose more preferred)
- Bladder irrigation along with polymyxin B

Framycetin

- Very similar to neomycin
- Too toxic for systemic administration
- Used topically on skin, eye ear